Letters sent to healthcare professionals in March 2018
Letters were sent to healthcare professionals about Zinbrytaâ–¼ (daclizumab beta), Lynparza 50 mg capsules, and radium-223-dichloride (Xofigoâ–¼).
In March 2018, letters were sent to healthcare professionals about:
- – for more information see Drug Safety Update, March 2018
- – for more information see Drug Safety Update, December 2017
Article citation: Drug Safety Update volume 11 issue 9; April 2018: 4.
Updates to this page
Published 24 April 2018